玻璃体腔内注射雷珠单抗对糖尿病视网膜病变合并黄斑水肿患者视网膜厚度的影响

Influence of Intravitreal Injection of Ranibizumab on Retinal Thickness in Patients with Diabetic Retinopathy Complicated with Macular Edema

目的探讨玻璃体腔内注射雷珠单抗对糖尿病视网膜病变合并黄斑水肿患者视网膜厚度的影响。方法选取2018年2月至2021年2月期间我院收治的98例糖尿病视网膜病变合并黄斑水肿患者,随机分为对照组和观察组各49例。对照组予以保守治疗(口服和血明目片联合卵磷脂络合碘胶囊),观察组在对照组基础上予以玻璃体腔内注射雷珠单抗。比较两组患者的黄斑中心凹视网膜厚度(CMT)、最佳矫正视力(BCVA)及不良反应情况。结果治疗1个月、3个月、6个月后,两组的CMT、BCVA均明显下降,且观察组的CMT、BCVA明显低于对照组(P<0.05)。两组的不良反应发生率(14.28%vs.10.20%)比较差异无统计学意义(P>0.05)。结论玻璃体腔内注射雷珠单抗能够有效改善糖尿病视网膜病变合并黄斑水肿患者的视网膜厚度,提高其视力。

Objective To explore the influence of intravitreal injection of ranibizumab on retinal thickness in patients with diabetic retinopathy complicated with macular edema.Methods 98 patients with with diabetic retinopathy complicated with macular edema admitted to our hospital from February 2018 to February 2021 were selected and randomly divided into control group and observation group,with 49 cases in each group.The control group was given conservative treatment(oral Hexuemingmu tablets combined with lecithin complexed iodine capsules),and the observation group was given intravitreal injection of ranibizumab on the basis of the control group.The central macular thickness(CMT),best corrected visual acuity(BCVA)and adverse reactions were compared between the two groups.Results After 1 months,3 months and 6 months of treatment,the CMT and BCVA of the two groups significantly decreased,and the CMT and BCVA of the observation group were significantly lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions(14.28%vs.10.20%)between the two groups(P>0.05).Conclusions Intravitreal injection of ranibizumab for patients with diabetic retinopathy complicated with macular edema can effectively improve the retinal thickness and visual acuity.